Viewing StudyNCT00410124



Ignite Creation Date: 2024-05-05 @ 5:14 PM
Last Modification Date: 2024-10-26 @ 9:29 AM
Study NCT ID: NCT00410124
Status: COMPLETED
Last Update Posted: 2013-01-15
First Post: 2006-12-11

Brief Title: RAD001 Plus Best Supportive Care BSC Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib andor Sunitinib
Sponsor: Novartis Pharmaceuticals
Organization: Novartis

Conditions & Keywords Data

Conditions:
Name
Metastatic Renal Cell Carcinoma
Keywords:
Name View
advanced kidney cancer View
everolimus View
kidney cancer View
oral therapy View